patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_711499 | REC_0005001 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.4 | 72 | female | 2 | 12 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.6 | false | MSS | 2026-03-15T05:35:58.083727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882958 | REC_0005002 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 15.3 | 72 | female | 1 | 9 | 5.9 | 2 | sotorasib 960 mg daily | 20.6 | true | MSS | 2026-03-15T05:35:58.083961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748835 | REC_0005003 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 5.6 | 73 | female | 0 | 43 | 6.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 23 | true | MSS | 2026-03-15T05:35:58.084279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939293 | REC_0005004 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.2 | 85 | female | 3 | 18 | 6.5 | 7 | entrectinib 600 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:58.084519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290141 | REC_0005005 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 15.9 | 67 | female | 1 | 15 | 6.2 | 2 | osimertinib 80 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:58.084757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402385 | REC_0005006 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 7.6 | 75 | female | 1 | 24 | 6.4 | 8 | pembrolizumab 200 mg q3w | 7.3 | false | MSS | 2026-03-15T05:35:58.085045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955911 | REC_0005007 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 14.1 | 54 | male | 0 | 16 | 6 | 4 | pembrolizumab 200 mg q3w | 8.8 | false | MSI-H | 2026-03-15T05:35:58.085289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260709 | REC_0005008 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.2 | 60 | male | 0 | 3 | 8 | 2 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:35:58.085523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517375 | REC_0005009 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.6 | 70 | female | 0 | 11 | 7.7 | 7 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:58.085761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845709 | REC_0005010 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.9 | 72 | male | 1 | 26 | 4.7 | 9 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:35:58.085992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943040 | REC_0005011 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.7 | 67 | male | 1 | 26 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:58.086225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152951 | REC_0005012 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 15.4 | 74 | female | 2 | 16 | 4.6 | 2 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:58.086458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448583 | REC_0005013 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.8 | 82 | female | 1 | 73 | 3.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 18 | false | MSS | 2026-03-15T05:35:58.086687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687926 | REC_0005014 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 17.5 | 69 | female | 1 | 10 | 5.2 | 1 | alectinib 600 mg BID | 23.1 | true | MSI-H | 2026-03-15T05:35:58.086926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956127 | REC_0005015 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 7 | 63 | female | 0 | 35 | 4.8 | 2 | pembrolizumab 200 mg q3w | 23.3 | false | MSS | 2026-03-15T05:35:58.087159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914383 | REC_0005016 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 31 | 16.3 | 73 | male | 2 | 18 | 6.3 | 0 | alectinib 600 mg BID | 34.6 | false | MSI-H | 2026-03-15T05:35:58.087392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911016 | REC_0005017 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 3.9 | 69 | male | 1 | 50 | 4.3 | 2 | pembrolizumab 200 mg q3w | 33.5 | true | MSS | 2026-03-15T05:35:58.087625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744860 | REC_0005018 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 9.6 | 65 | male | 0 | 7 | 5.7 | 7 | entrectinib 600 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:58.087856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997307 | REC_0005019 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 12.8 | 74 | female | 2 | 11 | 3.4 | 1 | pembrolizumab 200 mg q3w | 17.3 | false | MSS | 2026-03-15T05:35:58.088186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953545 | REC_0005020 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 17.6 | 67 | female | 1 | 18 | 5.8 | 7 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:58.088429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845043 | REC_0005021 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.2 | 71 | female | 1 | 19 | 5.9 | 1 | pembrolizumab 200 mg q3w | 26.1 | true | MSS | 2026-03-15T05:35:58.088663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155927 | REC_0005022 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 14.5 | 66 | female | 1 | 12 | 6.1 | 5 | entrectinib 600 mg daily | 8.7 | true | MSS | 2026-03-15T05:35:58.088904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519456 | REC_0005023 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 9.3 | 54 | female | 0 | 12 | 5.6 | 1 | osimertinib 80 mg daily | 23.4 | true | MSS | 2026-03-15T05:35:58.089138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291793 | REC_0005024 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.6 | 83 | female | 0 | 58 | 2 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:58.089367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441840 | REC_0005025 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 17 | 65 | female | 1 | 0 | 5.7 | 2 | sotorasib 960 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:35:58.089604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579185 | REC_0005026 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 14.4 | 71 | female | 2 | 13 | 6.2 | 1 | osimertinib 80 mg daily | 20.7 | true | MSS | 2026-03-15T05:35:58.089841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697157 | REC_0005027 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 15 | 67 | female | 0 | 9 | 4.7 | 2 | osimertinib 80 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:35:58.090077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388963 | REC_0005028 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 13.4 | 77 | female | 0 | 26 | 5.1 | 6 | osimertinib 80 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:58.090312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108931 | REC_0005029 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 3.1 | 59 | male | 0 | 15 | 4.6 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.090543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143938 | REC_0005030 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.3 | 71 | female | 1 | 20 | 5.8 | 5 | sotorasib 960 mg daily | 8 | false | MSS | 2026-03-15T05:35:58.090769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155337 | REC_0005031 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 10.3 | 74 | female | 2 | 11 | 4.2 | 2 | entrectinib 600 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.090999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309381 | REC_0005032 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 3.8 | 70 | female | 1 | 6 | 6 | 4 | sotorasib 960 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:58.091281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267704 | REC_0005033 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 12.2 | 64 | male | 0 | 23 | 3.6 | 0 | osimertinib 80 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:58.091523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130813 | REC_0005034 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 13.4 | 64 | female | 0 | 14 | 3.9 | 7 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.091757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277496 | REC_0005035 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13.9 | 70 | female | 2 | 9 | 4.3 | 1 | alectinib 600 mg BID | 22.6 | true | MSS | 2026-03-15T05:35:58.091990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833749 | REC_0005036 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 11.5 | 63 | male | 0 | 22 | 5.8 | 2 | osimertinib 80 mg daily | 24.1 | false | MSI-H | 2026-03-15T05:35:58.092258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449070 | REC_0005037 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.8 | 68 | female | 1 | 61 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.5 | false | MSS | 2026-03-15T05:35:58.092490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496008 | REC_0005038 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.6 | 69 | female | 0 | 26 | 6.2 | 6 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:58.092720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748905 | REC_0005039 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.7 | 50 | female | 0 | 11 | 4.4 | 7 | sotorasib 960 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:58.092954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336765 | REC_0005040 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 7.6 | 69 | female | 1 | 12 | 5.9 | 3 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:58.093183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763649 | REC_0005041 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.9 | 54 | female | 0 | 16 | 3.9 | 7 | sotorasib 960 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:35:58.093418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165891 | REC_0005042 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.3 | 66 | female | 0 | 4 | 5.3 | 6 | osimertinib 80 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:35:58.093649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173569 | REC_0005043 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.8 | 65 | male | 0 | 64 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | false | MSS | 2026-03-15T05:35:58.093884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481976 | REC_0005044 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.9 | 63 | male | 1 | 6 | 4 | 5 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.094118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799821 | REC_0005045 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 4.3 | 65 | female | 0 | 20 | 4.1 | 10 | osimertinib 80 mg daily | 6.1 | true | MSS | 2026-03-15T05:35:58.094401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294641 | REC_0005046 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 16 | 71 | female | 2 | 19 | 6 | 2 | alectinib 600 mg BID | 24.6 | false | MSI-H | 2026-03-15T05:35:58.094639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366593 | REC_0005047 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 16.4 | 50 | male | 0 | 20 | 5.9 | 2 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:35:58.094876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351782 | REC_0005048 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 3.1 | 56 | male | 0 | 47 | 5.7 | 7 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:35:58.095106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214775 | REC_0005049 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5 | 78 | female | 2 | 63 | 4.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:35:58.095334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421704 | REC_0005050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 14 | 71 | female | 1 | 28 | 4.2 | 4 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:58.095605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109073 | REC_0005051 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 7.8 | 67 | female | 1 | 12 | 5.7 | 7 | sotorasib 960 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:58.095839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812275 | REC_0005052 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 2.7 | 79 | female | 3 | 6 | 5.9 | 4 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:58.096165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255014 | REC_0005053 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7 | 73 | female | 3 | 35 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.5 | false | MSS | 2026-03-15T05:35:58.096483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659331 | REC_0005054 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 5.6 | 63 | female | 1 | 48 | 7.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.8 | true | MSS | 2026-03-15T05:35:58.096787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218994 | REC_0005055 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 13.8 | 72 | female | 2 | 11 | 4.8 | 0 | entrectinib 600 mg daily | 45.2 | false | MSS | 2026-03-15T05:35:58.097054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732988 | REC_0005056 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13.1 | 69 | female | 0 | 14 | 6.4 | 4 | entrectinib 600 mg daily | 8 | true | MSS | 2026-03-15T05:35:58.097311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310399 | REC_0005057 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13.4 | 61 | female | 0 | 23 | 6.8 | 6 | entrectinib 600 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:58.097569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242674 | REC_0005058 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.3 | 70 | female | 2 | 21 | 4.5 | 6 | sotorasib 960 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:58.097944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131333 | REC_0005059 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.1 | 62 | female | 0 | 13 | 4.5 | 4 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:35:58.098193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922698 | REC_0005060 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 7.2 | 67 | female | 1 | 11 | 4.6 | 6 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.098425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792043 | REC_0005061 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 9.9 | 65 | male | 1 | 18 | 5.1 | 9 | alectinib 600 mg BID | 8.6 | true | MSS | 2026-03-15T05:35:58.098662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518495 | REC_0005062 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 14.3 | 64 | female | 1 | 20 | 5.9 | 1 | pembrolizumab 200 mg q3w | 20.4 | false | MSI-H | 2026-03-15T05:35:58.098903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409018 | REC_0005063 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 12.2 | 77 | female | 2 | 18 | 5.7 | 5 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:35:58.099140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971903 | REC_0005064 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.8 | 78 | female | 2 | 19 | 6 | 8 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:35:58.099371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326313 | REC_0005065 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 2.9 | 61 | female | 1 | 44 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.4 | false | MSS | 2026-03-15T05:35:58.099611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946338 | REC_0005066 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 10.4 | 67 | female | 0 | 63 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:58.099846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407953 | REC_0005067 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10.2 | 77 | female | 2 | 18 | 7 | 2 | osimertinib 80 mg daily | 20.3 | true | MSI-H | 2026-03-15T05:35:58.100152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668271 | REC_0005068 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 6.3 | 74 | female | 2 | 29 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:58.100404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547383 | REC_0005069 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.9 | 64 | male | 0 | 33 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 26 | true | MSS | 2026-03-15T05:35:58.100644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579338 | REC_0005070 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9.8 | 75 | female | 1 | 5 | 6.2 | 5 | osimertinib 80 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:58.100873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915360 | REC_0005071 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 13.5 | 58 | male | 0 | 4 | 4.2 | 5 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:58.101214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868815 | REC_0005072 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.1 | 75 | female | 2 | 13 | 5.5 | 5 | alectinib 600 mg BID | 15.2 | true | MSI-H | 2026-03-15T05:35:58.101455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840917 | REC_0005073 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 13.9 | 67 | female | 1 | 21 | 7.1 | 8 | alectinib 600 mg BID | 5.2 | false | MSS | 2026-03-15T05:35:58.101690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791956 | REC_0005074 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.2 | 79 | female | 1 | 36 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:35:58.101922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375905 | REC_0005075 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 14.4 | 69 | female | 1 | 20 | 5.5 | 0 | alectinib 600 mg BID | 33.9 | true | MSI-H | 2026-03-15T05:35:58.102168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982377 | REC_0005076 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 3.6 | 74 | female | 2 | 26 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:35:58.102409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434483 | REC_0005077 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 3.7 | 77 | female | 1 | 6 | 4.6 | 4 | entrectinib 600 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.102639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706498 | REC_0005078 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 6.9 | 71 | female | 1 | 5 | 7.8 | 7 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:58.102868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712162 | REC_0005079 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 15.9 | 54 | male | 0 | 6 | 6.5 | 5 | osimertinib 80 mg daily | 6.5 | true | MSI-H | 2026-03-15T05:35:58.103108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962671 | REC_0005080 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 37 | 13 | 77 | female | 2 | 10 | 4.4 | 1 | entrectinib 600 mg daily | 20.7 | true | MSS | 2026-03-15T05:35:58.103344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954089 | REC_0005081 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 14.8 | 68 | male | 0 | 1 | 4.2 | 2 | entrectinib 600 mg daily | 30.5 | false | MSS | 2026-03-15T05:35:58.103582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202133 | REC_0005082 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 11.9 | 67 | female | 0 | 14 | 5.9 | 7 | entrectinib 600 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:58.103818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688988 | REC_0005083 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 14.7 | 54 | female | 0 | 22 | 5 | 5 | entrectinib 600 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:58.104053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868748 | REC_0005084 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 7.3 | 64 | male | 1 | 50 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.7 | true | MSS | 2026-03-15T05:35:58.104523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469615 | REC_0005085 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.4 | 77 | male | 1 | 20 | 6.9 | 3 | alectinib 600 mg BID | 17.2 | true | MSI-H | 2026-03-15T05:35:58.104782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179539 | REC_0005086 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 5.9 | 78 | female | 2 | 19 | 4.7 | 5 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:58.105018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775588 | REC_0005087 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 17 | 59 | female | 1 | 24 | 4.3 | 2 | sotorasib 960 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:58.105256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659749 | REC_0005088 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.4 | 66 | female | 1 | 9 | 8.3 | 2 | pembrolizumab 200 mg q3w | 18.8 | true | MSI-H | 2026-03-15T05:35:58.105488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394066 | REC_0005089 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 16.1 | 80 | female | 1 | 10 | 5.3 | 5 | osimertinib 80 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:35:58.105724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325698 | REC_0005090 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 13.6 | 61 | female | 1 | 14 | 4.4 | 0 | sotorasib 960 mg daily | 28.9 | false | MSI-H | 2026-03-15T05:35:58.105959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481462 | REC_0005091 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 7.7 | 61 | female | 1 | 11 | 5.4 | 7 | sotorasib 960 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:58.106189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809087 | REC_0005092 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 19.5 | 64 | male | 0 | 20 | 3.7 | 2 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:58.106426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854075 | REC_0005093 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 6.3 | 66 | female | 1 | 15 | 4.6 | 1 | sotorasib 960 mg daily | 25.1 | true | MSS | 2026-03-15T05:35:58.106655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265382 | REC_0005094 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.6 | 69 | female | 1 | 2 | 3.8 | 5 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:58.106884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885673 | REC_0005095 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 8.9 | 57 | female | 0 | 14 | 5 | 2 | osimertinib 80 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:58.107118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823728 | REC_0005096 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.7 | 70 | male | 1 | 10 | 5.4 | 2 | entrectinib 600 mg daily | 29.6 | true | MSI-H | 2026-03-15T05:35:58.107352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685153 | REC_0005097 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 11.9 | 65 | male | 0 | 11 | 5.2 | 1 | alectinib 600 mg BID | 14.8 | true | MSI-H | 2026-03-15T05:35:58.107653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656856 | REC_0005098 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 6.9 | 89 | female | 1 | 13 | 5.3 | 1 | sotorasib 960 mg daily | 12.9 | true | MSS | 2026-03-15T05:35:58.107886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100363 | REC_0005099 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.1 | 58 | female | 1 | 60 | 6 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.108199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403759 | REC_0005100 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 35 | 4.1 | 83 | female | 1 | 14 | 4.6 | 6 | pembrolizumab 200 mg q3w | 12.4 | false | MSS | 2026-03-15T05:35:58.108451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.